Results 131 to 140 of about 8,380,026 (270)

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas

The Oncologist, 2022
Villani, Alessia, Fabbrocini, Gabriella, Costa, Claudia, Potestio, Luca, Scalvenzi, Massimiliano   +4 more
openaire   +3 more sources

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

A comparative analysis of Mohs micrographic surgery with or without photodynamic therapy for locally advanced basal cell carcinoma

Photodiagnosis and Photodynamic Therapy
Background: Locally advanced basal cell carcinoma (laBCC) is a more severe subtype of BCC, characterized by large, deeply invasive tumors that often occur in cosmetically or functionally sensitive areas.
Freddy Gahimbare, Xurong Liu, Jipang Zhan, Yanyu Du, Renliang He, Lian Zhang   +5 more
doaj   +1 more source

Topical and systemic medical treatments of basal cell carcinoma

, 2015
Basal cell carcinoma (BCC) is the most common non melanoma skin cancer (NMSC) in white individuals over the age of 40 years. BCCs usually grow slowly and rarely metastasize, but can be locally invasive if neglected or of an aggressive subtype.
Peris, Ketty
core  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy

, 2017
Zoe Apalla,1 Chrysoula Papageorgiou,1 Aimilios Lallas,1 Elena Sotiriou,1 Elizabeth Lazaridou,1 Efstratios Vakirlis,1 Athanassios Kyrgidis,2 Demetrios Ioannides1 1First Department of Dermatology, Aristotle University, 2Department of Oral and Maxillofacial
Ioannides D, Vakirlis E, Sotiriou E, Papageorgiou C, Lallas A, Apalla Z, Kyrgidis A, Lazaridou E   +7 more
core  

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

Locally Advanced Unresectable Basal Cell Carcinoma [PDF]

, 2020
openaire   +1 more source